Precision oncology reveals new opportunities for patients with malignant diseases. This is based on the rapid developments of diagnostic tools, which allow to identifying oncogenic alterations in common as well as in rare malignancies and may provide patients access to targeted treatment options. The Comprehensive Cancer Center Zürich offers a wide range of platforms for molecular analysis of tumors and liquid biopsies and has established a molecular tumor board, which meets weekly to interpret molecular results and make recommendations for therapy. At the first Zürich Precision-Oncology Symposium, a panel of national and international experts will provide an overview and discuss recent developments of the field.

According to ASH, abstracts submitted for oral and poster presentations at the ASH annual meeting represent important, novel research in the field and are considered the best of the thousands of abstracts submitted. Typically, more than 5,000 scientific abstracts are submitted each year and more than 3,000 abstracts are accepted for oral and poster presentations through an extensive peer review process. Please see a choice of oral and poster abstracts with conclusions and links to the whole abstract. Oncoletter presents you the webcasts from the press briefings where important studies have been presented. Until December 18 there will be more webcasts with opinions from experts based in Switzerland about studies which were presented at ASH 2018.

We invite you to take part in the Third Zürich Immuno-Oncology Symposium recorded by Oncoletter.ch and organized by the Comprehensive Cancer Center Zürich where a panel of renowned national and international experts will provide you with an overview of the field.

As part of the National Strategy against Cancer, the international symposium on digital tools designed to promote self-efficacy for cancer patients brings together representatives of patient organisations and healthcare, social work and medical experts as well as providers of digital solutions (eHealth und mHealth). The meeting addresses the current state of developments from various perspectives.

According to the organizer the ESMO 2017 Congress, in partnership with the European Association for Cancer Research (EACR), will bring cancer researchers and clinicians together to enable collaboration and the exchange of ideas, from the laboratory to the bedside and back. This exciting partnership creates a unique cancer congress in Europe with huge scientific reach and the true potential to improve the lives of cancer patients. The ESMO Congress is the most influential annual meeting for oncology professionals in Europe. Oncoletter ist proud presenting you some of the highlights of this years ESMO 2017 congress.

Welcome to the Oncoletter Report from the ESMO 19th World Congress on Gastrointestinal Cancer, the premier global congress on GI malignancies. Oncoletter is focusing its report on colorectal & pancreatic cancer.

Oncoletter reports from ASCO 2017. The press conference files were recorded by ASCO. Oncoletter provides the links to these press conferences which report some of the most important studies having been presented at asco 2017. In addition Oncoletter presents some interviews about studies and other highlights having been presented at ASCO 2017.

The Cancer Center Zürich and its Thoracic Oncology Center are proud to invite you for a full day of scientific exchange, and its members are looking forward seeing and discussing with you the current and future developments which are bringing new hope for our patients.

An international scientific symposium for interaction and exchange among basic scientists and clinicians in breast cancer.

Oncoletter presents the highlights from the ASH 2016 in San Diego - Webcasts from the Press Conferences and a Choice of Oral Sessions - partly wit Slides - and a Talk with Christoph Renner and Christian Taverna.

The annual ESMO congress is the premier scientific platform to present your oncology research and as such, the ultimate learning experience for congress attendees. Oncoletter presents the highlights of the congress such as the most important late breaking studies, slides, interviews and statements.

As Prof. Dr. Rolf Stahel, Chair and Prof. Dr. Michael Weller Deputy Chair both Cancer Center Zürich Cancer Center Zürich are writing in their welcome to the partcipants of the First Zurich Immuno-Oncology Symposium Immunotherapy with immune checkpoint inhibitors has become a reality for patients with metastatic melanoma and patients with advanced non-smallcell lung cancer with progressive disease after first line chemotherapy. Available data indicate patients with many other malignant diseases are likely to benefit from this form of therapy. The advent of immunotherapy brings new opportunities, but also new challenges to physicians advising patients and treating patients. Oncoletter received the permission to videotape this symposium and invites you in the words of Profs. Stahel and Weller to take part in the First Zurich Immuno-Oncology Symposium of the Cancer Center Zürich to familiarize yourself with the new developments.

Thank you for visiting Oncoletter's website report from the ESMO 18th World Congress on Gastrointestinal Cancer. The 18th year of the largest Congress specifically designed for practicing clinicians, gastroenterologists, hepatologists, surgeons, medical oncologists, radiation oncologists, and clinical researchers who wish to review and update their knowledge and management of cancers of the gastrointestinal tract was a great success.

The EHAs educational and scientific program will highlight state-of-the art clinical practice, the latest findings in hematology research and many more interesting sessions. Oncoletter is proud to present you some of the conference highlights. These highlights were presented at two press briefings, which were videotaped by oncoletter and are shown below.You will also find a comment from Prof. Markus Manz, USZ, on the TOWER-Study with blinatumomab in ALL. In addition there are a choice of posters and abstracts e.g. in the field of Multiple Myeloma & Lymphoma. The Multiple Myeloma section contains a comment from Antonio Palumbo, Turin, on the meta-analysis of the overall survival with LEN maintenance after HD-MEL & ASCT.

Bladder Cancer Highlights from the 31st Annual EAU Congress (EAU16)

Freitag 22. April 2016

The Best of EAU16 brings you the highlights from the 31st Annual EAU Congress (EAU16). One of the most popular topics in Munich was Bladder Cancer. Experts in the field have selected the best that EAU16 has to offer on bladder cancer, varying from webcast and abstracts to reports and debates. Please enjoy this selection of free previews from the EAU16 Resource Centre!

Multidisciplinary in content and scope, the 2016 Gastrointestinal (GI) Cancers Symposium brings together a diverse group of stakeholders involved in the prevention, detection, and treatment of GI cancers. Oncoletter is presenting a choice of studies including webcasts and slides.

US Vice-President Joe Biden convenes international leaders in cancer research, cancer treatment and data science to discuss potential opportunities to advance the pace of progress in the fight against cancer.

The Mission of The European Cancer Organisation is To achieve the best possible patient outcomes – taking into consideration the trends that impact on cancer, the complexity of the disease, and the specificity of each cancer patient.

Oncoletter is presenting some of the highlights which were discussed at the press conferences and during interviews done by Oncoletter in cooperation with Brustkrebs Deutschland e.V. and discussions produced by medONLINE in cooperation with oncoletter.ch (more info@Immuno-Oncology Info Center).

Thank you for visiting Oncoletter's website report from the ESMO 17th World Congress on Gastrointestinal Cancer. Oncoletter presents the results of the Session XVIII: Metastatic colorectal cancer together with a comment from TBA. In addition there will be some Information presented - released by the organizers - on topics such as pancreas cancer, esophagal & gastric cancer.

The 13th International Conference on Malignant Lymphoma, the most important international forum devoted to basic and clinical research in lymphoid neoplasms presents Basic and clinical data during the sessions, focused not on a specific morphologic subtype, but rather on pathways or other biological aspects (e.g. microenvironment, immune system, chromosomal abnormalities, etc.).

The International Scientific Committee and the local organizers invite you to join another (14th) outstanding «St. Gallen-Breast Cancer Conference» - this time in Vienna, Austria! Experts of virtually all major cooperative groups and centers world-wide actively engaged in basic and clinical research as well as in clinical management of breast cancer will present their latest data, critically reviewed by leading specialists in the field.

Webcasts from sessions 1-13 except the session 14 (consensus session) will be available within 14 days after the conference has ended (as of April 4, 2015).

The premier event in malignant & non-malignant hematology

December 6-9, 2014, Moscone Center, San Francisco, CA

Panel discussion of some of the main highlights in thoracic oncology of the year 2014, filmed at the ETOP Annual Meeting in Vienna November 14, 2014. Produced by ETOP & Oncoletter through economic support by Amgen, BMS and Eli Lilly.

ESMO 2014 promises to be an exciting meeting, merging state-of-the-art oncology with the latest breakthrough discoveries, from cost-effective anti-cancer treatments to best supportive care.

Among the numerous studies presented e.g. in the field of melanoma and colorectal cancer, the ESMO Press & Media Affairs Committee has selected some topics and abstracts for presentation to the press due to their particular importance for clinical practice and patient care.

The American Society of Hematology (ASH) invites you to New Orleans, LA, for its 55th annual meeting. As the premier hematology event of the year, this meeting is an invaluable educational experience for all attendees and Oncoletter provides the latest news from the conference.

Erivedge® (Vismodegib) for the Treatment of advanced Basal Cell Carcinoma. Talk of Prof. Dr. Rainer Kunstfeld, Assoc. Professor of Dermatology, Senior Consultant Dept. of Dermatology, Medical University Vienna, Austria – Held on the 26th of September 2013 as part of the lecture “Topical and systemic chemotherapy & photodynamic therapy”- Organized by the Swiss Society of Oto-Rhino-Laryngology, Head and Neck Surgery

The 17th ECCO – 38th ESMO – 32nd ESTRO European Cancer Congress is organised in partnership with ESSO 33, EACR, EONS and SIOPE. The European Cancer Congresses are consequently the only multidisciplinary and multi-professional educational opportunity in oncology to take place in Europe – a fact that underpins the relevance, role and participation of each and every speciality in oncology.

The ESMO 15th World Congress in Gastrointestinal Cancer is the premier global event in the field, encompassing malignancies affecting every component of the gastrointestinal tract and aspects related to the care of patients with gastrointestinal cancer, including screening, diagnosis and the latest management options for common and uncommon tumours. Oncoletter provides the slides of a selection of studies presented at the conference such as the SAKK-study and the updated results of the FIRE-3 study with a video comment from Prof. Volker Heinemann, Munich.

News

In the largest study so far undertaken, US researchers have shown that testosterone replacement slows the recurrence of prostate cancer in low-risk patients. This may call into question the general applicability of Nobel-Prize winning hormonal prostate treatment. The work is presented at the European Association of Urology congress in Barcelona.